PsyBio Therapeutics Corp (TSXV:PSYB) (OTCMKTS:PSYBF) CEO Evan Levine tells Proactive it is starting to manufacture proprietary biosynthetic psychedelic compounds in Europe. Tevine says the initial pilot-scale batch manufacturing run is the Florida-based company’s first in the continent, and is working with France’s Biose Industrie, which commercializes pharmaceutical products based on live bacterial production.
PsyBio Therapeutics begins European manufacturing of its proprietary biosynthetic compounds
